Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Kamada

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin

Details:

The study of KEDRAB® (Rabies Immune Globulin [Human]) conducted in children was the first and only pediatric study for any HRIG available in U.S. The study met its primary objective, which was to confirm the safety of KEDRAB in the pediatric population.

Lead Product(s): Rabies Immune Globulin [Human]

Therapeutic Area: Infections and Infectious Diseases Product Name: Kedrab

Highest Development Status: Phase IV Product Type: Vaccine

Partner/Sponsor/Collaborator: Kedrion

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY